These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29154807)

  • 21. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
    Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication.
    Delang L; Vliegen I; Froeyen M; Neyts J
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4103-13. PubMed ID: 21709100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
    Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
    Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct-acting and host-targeting HCV inhibitors: current and future directions.
    Chatel-Chaix L; Germain MA; Götte M; Lamarre D
    Curr Opin Virol; 2012 Oct; 2(5):588-98. PubMed ID: 22959589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral resistance and direct-acting antiviral agents for HCV.
    Aloia AL; Locarnini S; Beard MR
    Antivir Ther; 2012; 17(6 Pt B):1147-62. PubMed ID: 23188771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells.
    Lin K; Kwong AD; Lin C
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4784-92. PubMed ID: 15561857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance.
    Le Pogam S; Jiang WR; Leveque V; Rajyaguru S; Ma H; Kang H; Jiang S; Singer M; Ali S; Klumpp K; Smith D; Symons J; Cammack N; Nájera I
    Virology; 2006 Aug; 351(2):349-59. PubMed ID: 16713611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection.
    Koizumi Y; Ohashi H; Nakajima S; Tanaka Y; Wakita T; Perelson AS; Iwami S; Watashi K
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1922-1927. PubMed ID: 28174263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 3-Amino-2(5H)furanones as inhibitors of subgenomic hepatitis C virus RNA replication.
    Iannazzo D; Piperno A; Romeo G; Romeo R; Chiacchio U; Rescifina A; Balestrieri E; Macchi B; Mastino A; Cortese R
    Bioorg Med Chem; 2008 Nov; 16(21):9610-5. PubMed ID: 18835180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of whole genome sequencing in the Dutch Acute HCV in HIV study: focus on transmitted antiviral resistance.
    Christiansen MT; Hullegie SJ; Schutten M; Einer-Jensen K; Tutill HJ; Breuer J; Rijnders BJA
    Clin Microbiol Infect; 2017 Feb; 23(2):123.e1-123.e4. PubMed ID: 27693529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colony-forming assays reveal enhanced suppression of hepatitis C virus replication using combinations of direct-acting antivirals.
    Graham EJ; Hunt R; Shaw SM; Pickford C; Hammond J; Westby M; Targett-Adams P
    J Virol Methods; 2011 Jun; 174(1-2):153-7. PubMed ID: 21473883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of novel carbocyclic versions of 2'-spirocyclopropyl ribonucleosides as potent anti-HCV agents.
    Oh CH; Kim E; Hong JH
    Nucleosides Nucleotides Nucleic Acids; 2011 Jun; 30(6):423-39. PubMed ID: 21780908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C virus-specific directly acting antiviral drugs.
    Delang L; Neyts J; Vliegen I; Abrignani S; Neddermann P; De Francesco R
    Curr Top Microbiol Immunol; 2013; 369():289-320. PubMed ID: 23463206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.
    Serre SB; Jensen SB; Ghanem L; Humes DG; Ramirez S; Li YP; Krarup H; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3563-78. PubMed ID: 27021330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice.
    Uchida T; Hiraga N; Imamura M; Yoshimi S; Kan H; Miyaki E; Tsuge M; Abe H; Hayes CN; Aikata H; Ishida Y; Tateno C; Ellis JD; Chayama K
    Virus Res; 2016 Feb; 213():62-68. PubMed ID: 26569595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of antiviral drug synergy in an infectious HCV system.
    Lin B; He S; Yim HJ; Liang TJ; Hu Z
    Antivir Ther; 2016; 21(7):595-603. PubMed ID: 27035622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current approaches for developing new anti-HCV agents and analyses of HCV replication using anti-HCV agents].
    Watashi K; Shimotohno K
    Uirusu; 2005 Jun; 55(1):105-10. PubMed ID: 16308536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced fitness of hepatitis C virus increases resistance to direct-acting antivirals.
    Soni S; Singh D; Aggarwal R; Veerapu NS
    J Gen Virol; 2022 Feb; 103(2):. PubMed ID: 35133954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experimental models for hepatitis C virus (HCV): new opportunities for combating hepatitis C.
    Trujillo-Murillo Kdel C; Garza-Rodríguez Mdel L; Martínez-Rodríguez HG; Barrera-Saldaña HA; Bosques-Padilla F; Ramos-Jiménez J; Rivas-Estilla AM
    Ann Hepatol; 2004; 3(2):54-62. PubMed ID: 15257247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substituted imidazopyridines as potent inhibitors of HCV replication.
    Vliegen I; Paeshuyse J; De Burghgraeve T; Lehman LS; Paulson M; Shih IH; Mabery E; Boddeker N; De Clercq E; Reiser H; Oare D; Lee WA; Zhong W; Bondy S; Pürstinger G; Neyts J
    J Hepatol; 2009 May; 50(5):999-1009. PubMed ID: 19303654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.